These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 35820519)
1. Pharmacokinetics, biodistribution, and activity of Amphotericin B-loaded nanocochleates on the Leishmania donovani murine visceral leishmaniasis model. Lipa Castro A; Pomel S; Cailleau C; Fournier N; Dennemont I; Loiseau PM; Barratt G Int J Pharm; 2022 Aug; 624():121985. PubMed ID: 35820519 [TBL] [Abstract][Full Text] [Related]
2. Cochleate formulations of Amphotericin b designed for oral administration using a naturally occurring phospholipid. Lipa-Castro A; Nicolas V; Angelova A; Mekhloufi G; Prost B; Chéron M; Faivre V; Barratt G Int J Pharm; 2021 Jun; 603():120688. PubMed ID: 33965540 [TBL] [Abstract][Full Text] [Related]
3. In vitro activity of amphotericin B cochleates against Leishmania chagasi. Sesana AM; Monti-Rocha R; Vinhas SA; Morais CG; Dietze R; Lemos EM Mem Inst Oswaldo Cruz; 2011 Mar; 106(2):251-3. PubMed ID: 21537689 [TBL] [Abstract][Full Text] [Related]
4. Amphotericin B: A drug of choice for Visceral Leishmaniasis. Kumari S; Kumar V; Tiwari RK; Ravidas V; Pandey K; Kumar A Acta Trop; 2022 Nov; 235():106661. PubMed ID: 35998680 [TBL] [Abstract][Full Text] [Related]
5. In-vitro and in-vivo antileishmanial activity of inexpensive Amphotericin B formulations: Heated Amphotericin B and Amphotericin B-loaded microemulsion. Rochelle do Vale Morais A; Silva AL; Cojean S; Balaraman K; Bories C; Pomel S; Barratt G; do Egito EST; Loiseau PM Exp Parasitol; 2018 Sep; 192():85-92. PubMed ID: 30075233 [TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics and Biodistribution of Single-Dose Liposomal Amphotericin B at Different Stages of Experimental Visceral Leishmaniasis. Voak AA; Harris A; Qaiser Z; Croft SL; Seifert K Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630200 [TBL] [Abstract][Full Text] [Related]
7. Bioinspired Calcium Phosphate Nanoparticles Featuring as Efficient Carrier and Prompter for Macrophage Intervention in Experimental Leishmaniasis. Chaurasia M; Singh PK; Jaiswal AK; Kumar A; Pawar VK; Dube A; Paliwal SK; Chourasia MK Pharm Res; 2016 Nov; 33(11):2617-29. PubMed ID: 27401407 [TBL] [Abstract][Full Text] [Related]
8. Exploitation of lectinized lipo-polymerosome encapsulated Amphotericin B to target macrophages for effective chemotherapy of visceral leishmaniasis. Gupta PK; Asthana S; Jaiswal AK; Kumar V; Verma AK; Shukla P; Dwivedi P; Dube A; Mishra PR Bioconjug Chem; 2014 Jun; 25(6):1091-102. PubMed ID: 24842628 [TBL] [Abstract][Full Text] [Related]
9. Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum. Gangneux JP; Sulahian A; Garin YJ; Derouin F Trans R Soc Trop Med Hyg; 1996; 90(5):574-7. PubMed ID: 8944278 [TBL] [Abstract][Full Text] [Related]
10. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome. Gangneux JP; Sulahian A; Garin YJ; Farinotti R; Derouin F Antimicrob Agents Chemother; 1996 May; 40(5):1214-8. PubMed ID: 8723469 [TBL] [Abstract][Full Text] [Related]
12. Chitosan coated PluronicF127 micelles for effective delivery of Amphotericin B in experimental visceral leishmaniasis. Singh PK; Pawar VK; Jaiswal AK; Singh Y; Srikanth CH; Chaurasia M; Bora HK; Raval K; Meher JG; Gayen JR; Dube A; Chourasia MK Int J Biol Macromol; 2017 Dec; 105(Pt 1):1220-1231. PubMed ID: 28780414 [TBL] [Abstract][Full Text] [Related]
13. Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice. Gershkovich P; Wasan EK; Sivak O; Li R; Zhu X; Werbovetz KA; Tidwell RR; Clement JG; Thornton SJ; Wasan KM J Antimicrob Chemother; 2010 Mar; 65(3):535-7. PubMed ID: 20026611 [TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome Wijnant GJ; Van Bocxlaer K; Yardley V; Harris A; Alavijeh M; Silva-Pedrosa R; Antunes S; Mauricio I; Murdan S; Croft SL Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):223-228. PubMed ID: 29673889 [TBL] [Abstract][Full Text] [Related]
15. Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses. Banerjee A; De M; Ali N J Immunol; 2008 Jul; 181(2):1386-98. PubMed ID: 18606693 [TBL] [Abstract][Full Text] [Related]
17. Antileishmanial activity, uptake, and biodistribution of an amphotericin B and poly(α-Glutamic Acid) complex. Mohamed-Ahmed AH; Seifert K; Yardley V; Burrell-Saward H; Brocchini S; Croft SL Antimicrob Agents Chemother; 2013 Oct; 57(10):4608-14. PubMed ID: 23796924 [TBL] [Abstract][Full Text] [Related]
18. Development of targeted 1,2-diacyl-sn-glycero-3-phospho-l-serine-coated gelatin nanoparticles loaded with amphotericin B for improved in vitro and in vivo effect in leishmaniasis. Khatik R; Dwivedi P; Khare P; Kansal S; Dube A; Mishra PR; Dwivedi AK Expert Opin Drug Deliv; 2014 May; 11(5):633-46. PubMed ID: 24606222 [TBL] [Abstract][Full Text] [Related]
19. Evaluating the potential of polyester nanoparticles for per oral delivery of amphotericin B in treating visceral leishmaniasis. Italia JL; Kumar MN; Carter KC J Biomed Nanotechnol; 2012 Aug; 8(4):695-702. PubMed ID: 22852479 [TBL] [Abstract][Full Text] [Related]
20. Amphotericin B loaded nanoemulsion: Optimization, characterization and in-vitro activity against L. donovani promastigotes. Prajapat VM; Aalhate M; Sriram A; Mahajan S; Maji I; Gupta U; Kumari D; Singh K; Kalia NP; Dua K; Singh SK; Singh PK Parasitol Int; 2024 Jun; 100():102848. PubMed ID: 38159836 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]